AstraZeneca Completes $600M Upfront License for Zegfrovy, Adding Global EGFR Lung Cancer Asset
AZN is trading near its 52-week low of $146.1 (11% above the low).
Summary
AstraZeneca completed its global license for Zegfrovy, paying $600M upfront with up to $900M in milestones. US launch planned for Q4 2026; 1st-line sNDA accepted by FDA.
Key Events · M&A and Partnerships · AZN
-
Zegfrovy Global License Completed
AstraZeneca closed its exclusive worldwide license with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for lung cancer.
-
Deal Terms: $600M Upfront, $900M Milestones
AstraZeneca pays $600 million upfront, up to $900 million in development, regulatory and sales milestones, plus tiered royalties on global sales.
-
US Launch Planned Q4 2026
Zegfrovy is already approved in the US and China for 2nd-line EGFR exon 20 insertion NSCLC; AstraZeneca will launch in the US during Q4 2026.
-
1st-Line sNDA Accepted by FDA
Supplemental NDA for 1st-line setting accepted by FDA, supported by WU-KONG28 Phase III data; also submitted to China CDE. Breakthrough Therapy Designation granted in both regions.
Analysis · AZN · Life Sciences
AstraZeneca has closed its exclusive global license for Zegfrovy (sunvozertinib), an oral EGFR inhibitor already approved in the US and China for 2nd-line EGFR exon 20 insertion NSCLC. The deal commits $600 million upfront with up to $900 million in milestones plus tiered royalties — a substantial capital outlay that deepens AstraZeneca's lung cancer franchise. A US launch is planned for Q4 2026, and a supplemental NDA for the 1st-line setting has been accepted by the FDA, with Breakthrough Therapy Designation in both the US and China. The transaction does not impact 2026 financial guidance.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 30% of the 1942 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $161.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $251.4B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.